Herbalife raised its 2014 net income guidance Tuesday after buying back hundreds of millions in stock.
Signet Jewelers said Wednesday it agreed to buy Zale Corp. for about $900 million to help it expand in North America.
Housing construction starts fell sharply in January, the U.S. Commerce Department said Wednesday, adding to a recent string of disappointing economic reports.
The stock market is little changed in early trading as investors wait to hear the latest news from the Federal Reserve.
U.S. stock futures were lower shortly before the market opened Wednesday as investors wait to hear from the Federal Reserve.
Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market included Coca-Cola, Rite Aid, Actavis and Google.
The New York Federal Reserve's manufacturing index for February came in at a positive 4.5, indicating modest growth in business activity.
Boeing says it has picked Everett, Wash., as the site to build wings for its new 777X passenger jet, and expects the site to maintain thousands of jobs in the area.
United Airlines passengers suffered widespread delays as the airline dealt with seemingly nationwide computer problems with its reservation system.
The world's largest ad buyers Magna Global has struck a deal with Google to commit $100 million to the tech company's properties.
Capella Education Co. beat analysts' estimates by 3 cents a share in the fourth quarter, but revenue declined slightly as total student enrollment decreased.
Medtronic reported that fiscal third quarter net profit fell 23 percent on expenses that included a charge related to discontinued testing of a high blood pressure treatment.
With America's poor showing in speedskating at the Olympics, Under Armour's image has taken a hit. But the company's response is gold-medal worthy.
Some investment strategists believe more money chasing fewer stocks has created a supply-and-demand dynamic that has led to higher stock prices.
Irish drugmaker Actavis expects to buy Forest Laboratories in a deal that will boost the company's presence in U.S. primary-care physicians' offices and bulk up its portfolio of branded drugs.